Skip to main content
رجوع
Watch Compare

Aptevo Therapeutics Inc.

جودة البيانات: 83%
APVO
Nasdaq Manufacturing Chemicals
KWD 4.37
▲ KWD 0.09 (2.10%)
القيمة السوقية: 5.16 M
السعر
KWD 4.37
القيمة السوقية
5.16 M
نطاق اليوم
KWD 4.25 — KWD 4.38
نطاق 52 أسبوعًا
KWD 3.80 — KWD 486.00
حجم التداول
15,186
فتح KWD 4.35
متوسط 50 يوم / 200 يوم
KWD 6.06
27.90% below
متوسط 50 يوم / 200 يوم
KWD 25.19
82.65% below

Quick Summary

النقاط الرئيسية

Negative free cash flow of -25.59 M

النمو

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-217.15%
أقل من متوسط القطاع (-53.41%)
ROIC-129.45%
Net MarginN/A
Op. MarginN/A

الأمان

Debt / Equity
N/A
Current Ratio4.03
Interest CoverageN/A

التقييم

PE (TTM)
-0.20
أعلى من متوسط القطاع (-1.48)
P/B Ratio0.30
EV/EBITDAN/A
Dividend YieldN/A

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Manufacturing (1364 نظير)
المقياس السهم وسيط القطاع
P/E -0.2 -1.5
P/B 0.3 1.6
ROE % -217.2 -53.4
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -25.97 M
ROE -217.15% ROA -121.85%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -25.59 M
ROIC -129.45% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 4.03
Interest Coverage N/A Asset Turnover N/A
Working Capital 17.04 M Tangible Book Value 17.39 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0.20 Forward P/E N/A
P/B Ratio 0.30 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -495.57%
Market Cap 5.16 M Enterprise Value -15.90 M
Per Share
EPS (Diluted TTM) -87.27 Revenue / Share N/A
FCF / Share -21.66 OCF / Share -21.66
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 98.56%
SBC-Adj. FCF -25.84 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — 3.11 M 3.11 M 12.29 M
Net Income -25.97 M -24.13 M -17.41 M 8.03 M -28.46 M
EPS (Diluted) -87.27 -87.38 -1.42 1.57 —
Gross Profit — — — — —
Operating Income -26.31 M -24.60 M -28.88 M -28.64 M -21.40 M
EBITDA — — — — —
R&D Expenses 14.54 M 14.38 M 17.11 M 17.88 M 18.99 M
SG&A Expenses — — — — —
D&A 240,000.0 352,000.0 567,000.0 901,000.0 1.14 M
Interest Expense — — — — —
Income Tax 0.0 — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 27.19 M 15.59 M 24.84 M 34.22 M 56.60 M
Total Liabilities 9.81 M 10.84 M 12.62 M 16.24 M 55.39 M
Shareholders' Equity 17.38 M 4.76 M 12.22 M 17.97 M 1.22 M
Total Debt — — 0.0 4.01 M 16.02 M
Cash & Equivalents 21.62 M 8.71 M 16.90 M 22.64 M 45.04 M
Current Assets 23.08 M 10.66 M 19.07 M 27.45 M 52.57 M
Current Liabilities 6.05 M 6.21 M 7.22 M 8.71 M 34.76 M